Developing novel inhibitors of malodour precursor transport in the human axilla.

开发人类腋窝恶臭前体运输的新型抑制剂。

• 批准号: BB/T002956/1
• 负责人: Simon Newstead
• 金额: $ 49.99万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FT002956%2F1
• 关键词: Developing; novel; inhibitors; malodour; precursor

Deodorants and antiperspirants are among the most important personal care products used every day. As consumers are demanding more from their personal care products, healthcare companies are constantly trying to improve the end-user experience of their products. Unilever, is the market leader with >40% market share, driven by sales of its 3 main brands, Rexona (Sure), Axe (Lynx) and Dove. Current product technology is based mainly on aluminium-containing antiperspirant salts (which also act as antimicrobials), antimicrobial solvents (ethanol, glycols) and fragrance. There is a demand for more targeted interventions, such as interfering directly with the formation of malodour at the molecular level. The production of body odour (BO) occurs during the normal growth of harmless bacterial communities that live on underarm skin, often called skin commensals or the skin microbiota. These bacteria acquire nutrients through the uptake of molecules secreted from the eccrine, sebaceous and apocrine glands in our skin. One of these molecules is a sulphur-conjugated peptide, which is secreted from the apocrine gland and recognised by a transport system designed to move peptides into the bacterial cell. Once inside the cell, the sulphur part of the molecule is split from the peptide and escapes from the bacteria, either through active transport or simple diffusion. Once on the skin, this volatile compound evaporates from the body and enters the air surrounding the individual as body odour. Inhibiting the bacterial transporter responsible for the uptake of the key precursor to thiol-based malodour represents a completely novel approach that holds great potential. For safety reasons, the market potential for a new odour-control technology lies, at least initially, in the non-aerosol segment, which represents about 10% of Unilever's business. The aim of this collaborative LINK award is therefore focused on developing a set of targeted inhibitors against the transport system responsible for the uptake of the odourless sulphur-conjugated peptide, thus eliminating one of the main causes of BO in the underarm. A commercialised peptide transporter inhibitor could potentially create a ~Euro200K per annum business for the new technology manufacturer. Furthermore, given the radical nature of the technology, its launch would be expected to result in significant market growth. This might mean growth of ~10% pa in the first 3 years for Unilever's non-aerosol business, equivalent to ~Euro300 million in cash turnover. There is thus clear potential to benefit the UK economy and to create new jobs for both the chemical supplier and Unilever, which has a global development and manufacturing site in Seacroft near Leeds.

除臭剂和止汗剂是每天使用的最重要的个人护理产品之一。随着消费者对个人护理产品的要求越来越高，医疗保健公司也在不断努力改善其产品的最终用户体验。联合利华是市场领导者，拥有超过40%的市场份额，主要由其3个主要品牌Rexona（Sure），Axe（Lynx）和Dove的销售推动。目前的产品技术主要基于含铝止汗剂盐（也可作为抗菌剂）、抗菌溶剂（乙醇、乙二醇）和香料。需要更有针对性的干预措施，例如在分子水平上直接干预恶臭的形成。体味（BO）的产生发生在生活在腋下皮肤上的无害细菌群落的正常生长过程中，这些细菌群落通常被称为皮肤微生物群或皮肤微生物群。这些细菌通过吸收我们皮肤中的外分泌腺、皮脂腺和顶浆分泌腺分泌的分子来获得营养。这些分子之一是硫结合肽，其从顶泌腺分泌并被设计成将肽移动到细菌细胞中的运输系统识别。一旦进入细胞，分子的硫部分从肽中分离出来，并通过主动运输或简单扩散从细菌中逃逸。一旦接触到皮肤，这种挥发性化合物就会从身体蒸发，并作为体臭进入人体周围的空气。抑制细菌转运蛋白负责摄取硫醇基恶臭的关键前体，这是一种具有巨大潜力的全新方法。出于安全原因，一种新的气味控制技术的市场潜力在于，至少在最初阶段，非气溶胶部分，这占联合利华业务的10%左右。因此，这个合作LINK奖项的目的是专注于开发一套针对负责吸收无味硫缀合肽的运输系统的靶向抑制剂，从而消除腋下BO的主要原因之一。商业化的肽转运蛋白抑制剂可能为新技术制造商创造每年约20万欧元的业务。此外，鉴于该技术的激进性质，预计其推出将导致市场大幅增长。这可能意味着联合利华非气雾剂业务在前3年每年增长约10%，相当于现金周转额约3亿欧元。因此，有明显的潜力有利于英国经济，并为化学品供应商和联合利华创造新的就业机会，联合利华在利兹附近的西克罗夫特拥有全球开发和制造基地。